Citation
Ju, Bin, et al. "Human Neutralizing Antibodies Elicited By SARS-CoV-2 Infection." Nature, vol. 584, no. 7819, 2020, pp. 115-119.
Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115-119.
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., Tang, X., Yu, J., Lan, J., Yuan, J., Wang, H., Zhao, J., Zhang, S., Wang, Y., Shi, X., ... Zhang, L. (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 584(7819), 115-119. https://doi.org/10.1038/s41586-020-2380-z
Ju B, et al. Human Neutralizing Antibodies Elicited By SARS-CoV-2 Infection. Nature. 2020;584(7819):115-119. PubMed PMID: 32454513.
TY - JOUR
T1 - Human neutralizing antibodies elicited by SARS-CoV-2 infection.
AU - Ju,Bin,
AU - Zhang,Qi,
AU - Ge,Jiwan,
AU - Wang,Ruoke,
AU - Sun,Jing,
AU - Ge,Xiangyang,
AU - Yu,Jiazhen,
AU - Shan,Sisi,
AU - Zhou,Bing,
AU - Song,Shuo,
AU - Tang,Xian,
AU - Yu,Jinfang,
AU - Lan,Jun,
AU - Yuan,Jing,
AU - Wang,Haiyan,
AU - Zhao,Juanjuan,
AU - Zhang,Shuye,
AU - Wang,Youchun,
AU - Shi,Xuanling,
AU - Liu,Lei,
AU - Zhao,Jincun,
AU - Wang,Xinquan,
AU - Zhang,Zheng,
AU - Zhang,Linqi,
Y1 - 2020/05/26/
PY - 2020/03/13/received
PY - 2020/05/18/accepted
PY - 2020/5/27/pubmed
PY - 2020/8/13/medline
PY - 2020/5/27/entrez
SP - 115
EP - 119
JF - Nature
JO - Nature
VL - 584
IS - 7819
N2 - The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that is in urgent need of intervention1-3. The entry of SARS-CoV-2 into its target cells depends on binding between the receptor-binding domain (RBD) of the viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2)2,4-6. Here we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells from 8 individuals infected with SARS-CoV-2. We identified antibodies that potently neutralize SARS-CoV-2; this activity correlates with competition with ACE2 for binding to RBD. Unexpectedly, the anti-SARS-CoV-2 antibodies and the infected plasma did not cross-react with the RBDs of SARS-CoV or Middle East respiratory syndrome-related coronavirus (MERS-CoV), although there was substantial plasma cross-reactivity to their trimeric spike proteins. Analysis of the crystal structure of RBD-bound antibody revealed that steric hindrance inhibits viral engagement with ACE2, thereby blocking viral entry. These findings suggest that anti-RBD antibodies are largely viral-species-specific inhibitors. The antibodies identified here may be candidates for development of clinical interventions against SARS-CoV-2.
SN - 1476-4687
UR - https://www.unboundmedicine.com/medline/citation/32454513/Human_neutralizing_antibodies_elicited_by_SARS_CoV_2_infection_
L2 - https://doi.org/10.1038/s41586-020-2380-z
DB - PRIME
DP - Unbound Medicine
ER -